How effective is dasatinib in pulmonary fibrosis?

Dasatinib (Dasatinib), as a tyrosine kinase inhibitor, was initially mainly used to treat blood diseases such as chronic myeloid leukemia (CML). However, in recent years, with the in-depth research on the pathological mechanism of pulmonary fibrosis, the potential of dasatinib in anti-pulmonary fibrosis has gradually attracted attention.

Dasatinib inhibits the activity of multiple tyrosine kinases, including BCR-ABL, SRC family kinases, etc., thereby blocking the conduction of downstream signaling pathways and affecting cell proliferation, differentiation, migration, apoptosis and other processes. In pulmonary fibrosis, abnormal activation of these signaling pathways often leads to fibroblast proliferation, collagen deposition, and lung tissue remodeling, ultimately forming pulmonary fibrosis. Therefore, theoretically, dasatinib may reduce the degree of pulmonary fibrosis by inhibiting these signaling pathways.

In animal experiments, dasatinib has shown certain anti-pulmonary fibrosis effects. For example, in a mouse pulmonary fibrosis model induced by bleomycin, dasatinib can significantly improve pulmonary fibrosis, reduce hydroxyproline content (hydroxyproline is the main component of collagen, and its content can reflect the degree of pulmonary fibrosis), and inhibit neovascularization. These results suggest that dasatinib has potential antipulmonary fibrosis effects in animals.

Although dasatinib has shown certain anti-pulmonary fibrosis effects in animal experiments, its clinical efficacy in humans still needs further verification. Currently, there are some preliminary human clinical trials exploring the use of dasatinib in the treatment of pulmonary fibrosis. For example, a study published in the authoritative journal "EEBiomedicine" showed that dasatinib combined with quercetin (a plant pigment with the function of clearing senescent cells) can treat mild to moderate idiopathic pulmonary fibrosis. Dimensionalization of patients can significantly improve the patient's mobility, such as the walking distance of 6 minutes, the pace of walking 4 meters, and the time it takes to change from sitting to standing. However, the study also pointed out that dasatinib combined with quercetin treatment had no significant impact on physiological indicators such as lung function, clinical chemistry, and frailty index, and had certain side effects, including mild and moderate respiratory symptoms, skin irritation, gastrointestinal discomfort, etc.

Dasatinib may block the proliferation and activation of fibroblasts by inhibiting signaling pathways such as SRC family kinases, thereby reducing collagen deposition and lung tissue remodeling.

Research in recent years has shown that senescent cells play an important role in the process of pulmonary fibrosis. Dasatinib combined with anti-aging drugs such as quercetin may reduce the degree of pulmonary fibrosis by removing senescent cells. The process of pulmonary fibrosis is often accompanied by inflammatory response and oxidative stress damage. Dasatinib may reduce the inflammatory response and oxidative damage of lung tissue by inhibiting the release of inflammatory factors and its antioxidant effect.

The application of dasatinib in the treatment of pulmonary fibrosis still faces many challenges. First, more clinical trials are needed to verify its clinical efficacy and safety. Secondly, the side effects of dasatinib also need to be paid attention to, especially during long-term use. In addition, how to optimize the dosage and administration regimen of dasatinib to maximize its anti-pulmonary fibrosis effect and reduce side effects is also an important direction for future research.